Glen A. Taylor - 12 Feb 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Reporting relationship: 10%+ Owner
Issuer ticker: COCH
Reported as of: 12 Feb 2026
Net transaction value: +$7,500,000
SEC form: 4
Accepted by SEC: 17 Feb 2026, 13:35:17 UTC
Prior SEC filing: 08 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Glen A. Taylor

Key filing fact

Glen A. Taylor filed Form 4 for Envoy Medical, Inc. (COCH) on 17 Feb 2026.

Key facts

This page summarizes Glen A. Taylor's Form 4 filing for Envoy Medical, Inc. (COCH).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 13:35.

Change

Previous filing in this sequence was filed on 08 Sep 2025.
Current net transaction value: +$7,500,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001213971 Primary reporting owner

TAYLOR GLEN A

Relationship: 10%+ Owner
Address: C/O TAYLOR CORP, 1725 ROE CREST DR, N MANKALO
Signature: /s/ Glen A. Taylor
Signature date: 16 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCH transaction

Class A Common Stock

Purchase

Transaction value: $7,500,000
Shares: +18,750,000
Change %: +635%
Price: $0.4000
Shares after: 21,703,607
Date: 12 Feb 2026
Ownership: Direct

COCH holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,526,058
Date: 12 Feb 2026
Ownership: By Taylor Sports Group
Footnotes: F1

COCH holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,810,384
Date: 12 Feb 2026
Ownership: By GAT Funding, LLC
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCH transaction Derivative

Warrant Shares (Series A-1)

Purchase

Transaction value: $0
Shares: +11,250,000
Change %
Price: $0.000000
Shares after: 11,250,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 11,250,000
Exercise price: $0.4000
Footnotes: F3, F4

COCH transaction Derivative

Warrant Shares (Series A-2)

Purchase

Transaction value: $0
Shares: +18,750,000
Change %
Price: $0.000000
Shares after: 18,750,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 18,750,000
Exercise price: $0.4000
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person is the owner and chairman of Taylor Sports Group.

Footnote F2

GAT Funding, LLC is an entity controlled by Reporting Person.

Footnote F3

The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").

Footnote F4

The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").

Footnote F5

The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").